News | Nuclear Imaging | January 27, 2020

The key factors driving the growth the radiopharmaceuticals market are increasing incidence and prevalence of cancer and cardiac ailments, and initiatives to lessen the demand-supply gap of Mo-99

Nuclear imaging of the spine shown on Philips Healthcare BrightView XCT

Image courtesy of Philips Healthcare


January 27, 2020 — According to the new market research report "Nuclear Medicine Market by Type (Diagnostic (SPECT - Technetium, PET- F-18), Therapeutic (Beta Emitters – I-131, Alpha Emitters, Brachytherapy – Y-90)), Application (Oncology, Cardiology) - Global Forecast to 2024", published by MarketsandMarkets, the nuclear medicine market is expected to reach USD 5.2 billion by 2024 from an estimated USD 4.1 billion in 2019, at a CAGR of 4.7 percent.

The key factors driving the growth of this radiopharmaceuticals market are increasing incidence and prevalence of cancer and cardiac ailments, and initiatives to lessen the demand-supply gap of Mo-99

SPECT radiopharmaceuticals segment expected to account for the largest share

Based on type, the market is categorized into diagnostic and therapeutic nuclear medicine. The diagnostic nuclear medicine segment is further categorized into SPECT and PET radiopharmaceuticals. The SPECT radiopharmaceuticals segment is expected to account for the largest share of the market in 2019. However, the PET radiopharmaceutical segment is projected to register the highest CAGR during the forecast period. Although PET is more expensive than SPECT, advances in PET imaging and the introduction of new PET radiotracers are supporting its growth in the market.

North America to dominate the market in 2019

North America, Europe, the Asia Pacific, and the Rest of the World (RoW) are the regions considered for geographic analysis of the global nuclear medicine market study. North America is expected to account for the largest share of the global nuclear medicine industry. The growth of the market in North America can be attributed to the development of novel technologies for radioisotope production, government funding, and company initiatives in the region.

For more information: www.marketsandmarkets.com 


Related Content

News | Radiopharmaceuticals and Tracers

September 22, 2022 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time September 22, 2022
arrow
Feature | Contrast Media | By Christine Book

The theme “Everyday progress” seems appropriate for the imaging community in 2022. What a year it’s been. Supply ...

Time September 14, 2022
arrow
News | PET-CT

September 13, 2022 — For over 40 years the vision of Shared Medical Services (SMS) has been to provide innovative ...

Time September 13, 2022
arrow
News | SPECT-CT

September 12, 2022 — Royal Philips, a global leader in health technology, announced new milestones in the development of ...

Time September 12, 2022
arrow
News | Prostate Cancer

September 8, 2022 — In prostate cancer patients experiencing recurrence following a radical prostatectomy, imaging with ...

Time September 08, 2022
arrow
News | SPECT-CT

September 7, 2022 — The American Society of Nuclear Cardiology (ASNC) and three partner societies have come together to ...

Time September 07, 2022
arrow
News | Radiopharmaceuticals and Tracers

August 26, 2022 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time August 25, 2022
arrow
News | Proton Therapy

August 19, 2022 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology and the ...

Time August 19, 2022
arrow
News | SNMMI

August 16, 2022 — Mike Crosby of San Diego, California, has been elected to a two-year term as vice chair of the Patient ...

Time August 16, 2022
arrow
Feature | Magnetic Resonance Imaging (MRI) | Christine Book

August 10, 2022 — The imaging community has lost a legend, recognized for having revolutionized the field of diagnostic ...

Time August 10, 2022
arrow
Subscribe Now